JPMorgan Chase & Co. trimmed its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 818,671 shares of the biopharmaceutical company’s stock after selling 15,624 shares during the quarter. JPMorgan Chase & Co. owned about 2.19% of Sage Therapeutics worth $65,199,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. FMR LLC grew its holdings in Sage Therapeutics by 0.3% in the first quarter. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company’s stock worth $397,319,000 after purchasing an additional 15,451 shares during the period. BlackRock Inc. lifted its stake in shares of Sage Therapeutics by 10,082.5% in the first quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after buying an additional 2,835,006 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Sage Therapeutics by 10.8% in the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares in the last quarter. Palo Alto Investors LLC lifted its stake in shares of Sage Therapeutics by 9.1% in the first quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock valued at $78,316,000 after buying an additional 92,021 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of Sage Therapeutics in the first quarter valued at $35,493,000.

WARNING: “JPMorgan Chase & Co. Trims Holdings in Sage Therapeutics, Inc. (SAGE)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/12/jpmorgan-chase-co-trims-holdings-in-sage-therapeutics-inc-sage.html.

Sage Therapeutics, Inc. (SAGE) opened at 88.52 on Tuesday. Sage Therapeutics, Inc. has a 52-week low of $38.30 and a 52-week high of $90.80. The company’s 50 day moving average is $82.90 and its 200-day moving average is $74.77. The company’s market capitalization is $3.31 billion.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.63) by $0.25. During the same period in the prior year, the company posted ($1.08) EPS. Equities analysts anticipate that Sage Therapeutics, Inc. will post ($7.38) EPS for the current fiscal year.

A number of research firms have weighed in on SAGE. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Sage Therapeutics in a research note on Thursday, August 31st. Cowen and Company reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Sage Therapeutics in a research note on Friday, August 4th. BidaskClub lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Needham & Company LLC began coverage on shares of Sage Therapeutics in a research note on Monday, May 15th. They issued a “buy” rating and a $82.00 price objective on the stock. Finally, HC Wainwright raised their price objective on shares of Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Sage Therapeutics has an average rating of “Buy” and an average target price of $89.64.

Sage Therapeutics Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.